Profil
Joseph J.
Higgins is the founder of SalioGen Therapeutics, Inc. where he currently holds the titles of President, Director, and Chief Innovation Officer.
Postes actifs de Joseph Higgins
| Sociétés | Poste | Début |
|---|---|---|
SalioGen Therapeutics, Inc.
 SalioGen Therapeutics, Inc. BiotechnologyHealth Technology SalioGen Therapeutics, Inc. is a genetic medicine company based in Cambridge, MA. The company is advancing the Exact DNA Integration Technology (EDIT) platform, which is a mammal-derived genome engineering technology for use in potentially curative non-viral gene therapy. SalioGen Therapeutics has launched Gene Coding, a genetic medicine technology, to develop durable, broadly applicable genetic medicines using its EDIT platform. The company's mission is to transform the treatment paradigm for patients with inherited disorders. Jason F. Cole has been the CEO of the company since 2023. | Fondateur | 01/01/2020 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
SalioGen Therapeutics, Inc.
SalioGen Therapeutics, Inc. BiotechnologyHealth Technology SalioGen Therapeutics, Inc. is a genetic medicine company based in Cambridge, MA. The company is advancing the Exact DNA Integration Technology (EDIT) platform, which is a mammal-derived genome engineering technology for use in potentially curative non-viral gene therapy. SalioGen Therapeutics has launched Gene Coding, a genetic medicine technology, to develop durable, broadly applicable genetic medicines using its EDIT platform. The company's mission is to transform the treatment paradigm for patients with inherited disorders. Jason F. Cole has been the CEO of the company since 2023. | Health Technology |